Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17‐mediated autoimmunity in the CNS
Open Access
- 20 March 2012
- journal article
- review article
- Published by Wiley in Immunology & Cell Biology
- Vol. 90 (5), 505-509
- https://doi.org/10.1038/icb.2012.8
Abstract
Different viruses trigger pattern recognition receptor systems, such as Toll-like receptors or cytosolic RIG-I like helicases (RLH), and thus induce early type I interferon (IFN-I) responses. Such responses may confer protection until adaptive immunity is activated to an extent that the pathogen can be eradicated. Interestingly, the same innate immune mechanisms that are relevant for early pathogen defense have a role in ameliorating experimental autoimmune encephalomyelitis (EAE), a rodent model of human multiple sclerosis. We and others found that mice devoid of a component of the IFN-I receptor (Ifnar1−/−) showed significantly enhanced autoimmune disease of the central nervous system (CNS). A detailed analysis revealed that in wild-type mice IFN-I triggering of myeloid cells was instrumental in reducing brain damage. A more recent study indicated that similar to Ifnar1−/− mice, RLH-signaling-deficient mice showed enhanced autoimmune disease of the CNS as well. Moreover, when peripherally treated with synthetic RLH ligands wild-type animals with EAE disease showed reduced clinical scores. Under such conditions, IFN-I receptor triggering of dendritic cells had a crucial role. The therapeutic effect of treatment with RLH ligands was associated with negative regulation of Th1 and Th17 T-cell responses within the CNS. These experiments are consistent with the hypothesis that spatiotemporal conditions of, and cell types involved in, disease-ameliorating IFN-I responses differ significantly, depending on whether they were endogenously induced in the context of EAE pathogenesis within the CNS or upon therapeutic RLH triggering in the periphery. It is attractive to speculate that RLH triggering represents a new strategy to treat multiple sclerosis by stimulating endogenous immunoregulatory IFN-I responses.Keywords
This publication has 55 references indexed in Scilit:
- Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating diseaseImmunological Reviews, 2011
- IFN-α Mediates the Development of Autoimmunity both by Direct Tissue Toxicity and through Immune Cell Recruitment MechanismsThe Journal of Immunology, 2011
- T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitisNature Medicine, 2010
- Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and toleranceImmunological Reviews, 2010
- Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvantThe Journal of Experimental Medicine, 2009
- CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous systemBrain, 2009
- IL-12– and IL-23–modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibitionThe Journal of Experimental Medicine, 2008
- The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in miceJCI Insight, 2008
- Differential regulation of central nervous system autoimmunity by TH1 and TH17 cellsNature Medicine, 2008
- CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organsNature, 2006